Biocon Biologics and Yoshindo Inc. launch Ustekinumab Biosimilar in Japan
Biocon Biologics, subsidiary of Biocon, announced today that its commercial partner in Japan, Yoshindo Inc., has launched Ustekinumab BS Subcutaneous Injection [YD], a biosimilar to the reference product Stelara (ustekinumab). The biosimilar ustekinumab, developed and manufactured by Biocon Biologics, is commercialized and marketed in Japan by Yoshindo Inc.
Ustekinumab, a monoclonal antibody, is approved for the treatment of psoriasis vulgaris and psoriatic arthritis (PsA).
In April 2024, the Company entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize Ustekinumab in Japan upon regulatory approval. Biocon Biologics' biosimilar Ustekinumab BS Subcutaneous Injection [YD] was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan in December 2024.
Biocon Biologics has already launched Ustekinumab in the United States and Europe in February 2025 to help patients manage their chronic conditions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
India Today
12 hours ago
- India Today
Dr Reddy's shares jump over 3% today. Here's why
Dr Reddy's Laboratories shares rose over 3% on Thursday, emerging as the top gainer on the Nifty Pharma index, which climbed 1.4%. Around 1:03 pm, the stock was up 3.39% at Rs 1, surge follows the announcement of a strategic partnership with US-listed biotech firm Alvotech to develop a biosimilar version of Merck's blockbuster cancer drug Keytruda (pembrolizumab). The PD-1 inhibitor, used to treat multiple cancer types, is expected to generate $29.5 billion in global sales in 2024, making it one of the most valuable targets in the biosimilars the agreement, Dr Reddy's and Alvotech will share development and manufacturing responsibilities and retain commercialisation rights globally, with a few Israeli, CEO of Dr Reddy's, called the deal a 'major step' in the company's oncology strategy. 'This collaboration enhances our capabilities in immuno-oncology and reinforces our focus on affordable, high-quality treatment options,' he which already markets biosimilars of Humira and Stelara, sees this partnership as a way to further leverage its R&D and manufacturing platform. 'This agreement demonstrates our ability to accelerate development of key biosimilars,' said chairman and CEO Rbert market has reacted positively to the development. While Dr Reddy's shares are down 5.3% on a year-to-date basis, they have gained 10.5% in the past month. Analysts see the move as a strategic bet to boost the company's global presence in the competitive biosimilar Direct described the Keytruda biosimilar as a 'decent pipeline opportunity' despite expected competition. At a forward 12-month PE of 18.8, Dr Reddy's remains the third-cheapest stock on the Nifty Pharma oncology being a core focus area and biosimilars gaining momentum globally, the collaboration with Alvotech marks a critical step in Dr Reddy's long-term growth The views, opinions, recommendations, and suggestions expressed by experts/brokerages in this article are their own and do not reflect the views of the India Today Group. It is advisable to consult a qualified broker or financial advisor before making any actual investment or trading choices.)Must Watch
India Today
a day ago
- India Today
Duolingo offers $30,000 STEM scholarship for Indian women studying in the US
Duolingo English Test (DET), in partnership with the Office of the Principal Scientific Adviser (PSA) to the Government of India, has launched the 'DETermined' Scholarship — a prestigious opportunity for Indian women pursuing careers in STEM (Science, Technology, Engineering, and Mathematics). The scholarship provides a one-time grant of USD 30,000 (approximately Rs 25 lakh) to support tuition fees for full-time undergraduate or postgraduate programs in the United States, beginning Spring application process is now live and available via the Manthan portal, with a submission deadline of June 30, INDIAN WOMEN IN STEMThe DETermined Scholarship aims to address the persistent financial barriers faced by Indian women pursuing higher education in STEM abroad. According to UGC data, women's enrollment in STEM fields in India has increased to 42.6% in 2024, up from 38.4% in 2014. Despite this progress, access to global institutions remains limited due to financial constraints—something this initiative aims to change. In addition to funding, the program emphasises leadership, innovation, and social impact. Applicants are expected to demonstrate a commitment to returning to India after their studies and show potential to launch a startup or scalable STEM project that addresses real-world AND APPLICATION DETAILS Identify as female and be Indian citizens currently residing in IndiaadvertisementHave achieved at least 60% in science subjects from a recognised Indian institutionHold a Duolingo English Test score of 120 or abovePlan to pursue a full-time undergraduate or postgraduate STEM degree in a US university that accepts DET scoresThe application includes uploading academic transcripts, a minimum DET score, and a personal statement or short video outlining the applicant's STEM SELECTION PROCESS The DETermined Scholarship selection process comprises three stages:Initial screening: Submission of academic credentials, DET score, and a short write-up or video on STEM aspirations via the Manthan Impact Proposal Challenge: Shortlisted candidates must present a written (max 1,000 words) or video (5-minute) proposal solving a STEM problem affecting their community or the Interview: A virtual panel interview to assess the applicant's motivation, leadership, and potential to drive innovation in final winner will be announced in September 2025, after all evaluation rounds are TO APPLY FOR DETERMINED SCHOLARSHIPS 2025Candidates can apply by visiting the Manthan portal or Duolingo's official grants page. The portal provides a detailed, step-by-step application guide and updates on key dates and deadlines.
Hans India
2 days ago
- Hans India
Biocon gets CDSCO nod for generic diabetes drug
New Delhi: Biocon on Tuesday said it received approval from the government authorities for a generic diabetes medication – Liraglutide drug substance. Itswholly-owned subsidiary Biocon Pharma has received approval for its Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge), from the Drugs Controller General of India (CDSCO). The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus in adults, adolescents and children aged 10 years and above, as an adjunct to diet and exercise, the company said in a regulatory filing. "The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes," Biocon CEO and MD Siddharth Mittal said. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further, he added. "We are now gearing up to launch the product expeditiously through our commercialisation partners in India," Mittal stated.
